Medicare GLP-1 coverage expansion

What happened: Eli Lilly, a leading global healthcare company, saw its stock hit record highs following positive earnings and the expansion of Medicare coverage for its GLP-1 drugs. Starting April 26, 2023, millions of Medicare beneficiaries will gain access to obesity drugs, including Lilly's Mounjaro and Wegovy, through Medicare's new GLP-1 Bridge program. These drugs will be available for $50 per month, significantly reducing out-of-pocket costs.

Market impact: This narrative drives growth in the obesity and diabetes treatment sectors. Lilly's GLP-1 drugs, in particular, stand to benefit from expanded Medicare coverage, potentially increasing their patient base and sales. Competitors like Novo Nordisk, which also offers GLP-1 drugs, may face increased competition. The reduced cost for beneficiaries could also drive demand for these drugs, positively impacting the broader pharmaceutical industry.

What to watch next: On May 2, 2023, Lilly reports its Q1 2023 earnings, which will provide insights into the early impact of Medicare GLP-1 coverage expansion on its sales. Additionally, monitor the Centers for Medicare & Medicaid Services (CMS) for updates on the GLP-1 Bridge program's progress and potential extensions or modifications. Lastly, track Lilly's stock performance, as it serves as a bellwether for the broader pharmaceutical industry's response to this narrative.